Heres, S, Schmitz, FS, Leucht, S, Pajonk, FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol
2007; 22: 275–82.
Patel, MX, De Zoysa, N, Bernadt, M, David, A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol
2009; 23: 789–96.
Kane, J, Sanchez, R, Perry, P, Jin, N, Johnson, BR, Forbes, RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psych
2012; 73: 617–24.
Burris, KD, Molski, TF, Xu, C, Ryan, E, Tottori, K, Kikuchi, T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther
2002; 302: 381–9.
Croxtall, JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs
2012; 26: 155–83.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Guy, W. ECDEU Assessment Manual for Psychopharmacology – Revised. US Department of Health Services, 1976.
Hough, D, Gopal, S, Vijapurkar, U, Lim, P, Morozova, M, Eerdekens, M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res
2010; 116: 107–17.
Mallikaarjun, S, Kane, JM, Bricmont, P, McQuade, R, Carson, W, Sanchez, R, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res
2013; 150: 281–8.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, revised) (DSM-IV-TR). APA, 2000.
Andreasen, NC, Carpenter, WT Jr., Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry
2005; 162: 441–9.
Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl
1970; 212: 11–9.
Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry
1989; 154: 672–6.
Posner, K, Brent, D, Lucas, C, Gould, M, Stanley, B, Brown, G, et al. Columbia Suicide Severity Rating Scale. The Research Foundation for Mental Hygiene, Inc, 2008 (http://cssrs.columbia.edu/docs/C-SSRS_1_14_09_Baseline.pdf).
Jensen, MP, Chen, C, Brugger, AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain
2003; 4: 407–14.
Kane, JM, Eerdekens, M, Lindenmayer, JP, Keith, SJ, Lesem, M, Karcher, K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry
2003; 160: 1125–32.
Pigott, TA, Carson, WH, Saha, AR, Torbeyns, AF, Stock, EG, Ingenito, GG, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry
2003; 64: 1048–56.
Levine, SZ, Rabinowitz, J, Engel, R, Etschel, E, Leucht, S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res
2008; 98: 318–22.
Kasper, S, Lerman, MN, McQuade, RD, Saha, A, Carson, WH, Ali, M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol
2003; 6: 325–37.
Hasan, A, Falkai, P, Wobrock, T, Lieberman, J, Glenthoj, B, Gattaz, WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry
2013; 14: 2–44.
Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX, Korhonen, P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry
2011; 168: 603–9.
Rosenheck, RA, Krystal, JH, Lew, R, Barnett, PG, Fiore, L, Valley, D, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med.
2011; 364: 842–51.
Kirson, NY, Weiden, PJ, Yermakov, S, Huang, W, Samuelson, T, Offord, SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry
2013; 74: 568–75.
Kishimoto, T, Robenzadeh, A, Leucht, C, Leucht, S, Watanabe, K, Mimura, M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull
2014; 40: 192–213.